Results 21 to 30 of about 280,718 (307)
Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2
Clinical and Translational Science, 2021 The outbreak of the novel coronavirus severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2), the causative agent of coronavirus disease 2019 (COVID‐19) respiratory disease, led to a global pandemic with high morbidity and mortality.
Hualou Liang +4 more
doaj +1 more source
Pricing of drugs and donations: options for sustainable equity pricing. [PDF]
, 2001 Effective medicines exist to treat or alleviate many diseases which predominate in the developing world and cause high mortality and morbidity rates. Price should not be an obstacle preventing access to these medicines.
Ford, N, Herranz, E, Pérez-Casas, C
core +2 more sources
The Future of Generic Biologics: Should the United States “Follow-On” the European Pathway? [PDF]
, 2008 The United States is embarking on a biotechnology drug revolution. In the last few decades, biotech drugs have saved millions of lives, and the market for these miracle cures continues to grow at an astronomical rate.
Kaldre, Ingrid
core +4 more sources
Prescribing Behavior of General Practitioners for Generic Drugs [PDF]
International Journal of Environmental Research and Public Health, 2020 The factors influencing General Practitioners’ (GPs) prescribing behavior are diverse in terms of health care policies and regulations, GPs’ education and experience, demographic trends and disease profiles. Thus, it can be useful to analyze the specific local patterns, as they affect the quality of healthcare and the stability of the healthcare market.
Tuncay, Berna +3 more
openaire +6 more sources
CPT: Pharmacometrics & Systems Pharmacology, 2021 Establishing bioequivalence (BE) for dermatological drug products by conducting comparative clinical end point studies can be costly and the studies may not be sufficiently sensitive to detect certain formulation differences.
Eleftheria Tsakalozou +2 more
doaj +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2023 On November 30, 2021, the US Food and Drug administration (FDA) and the Center for Research on Complex Generics (CRCG) hosted a virtual public workshop titled “Establishing the Suitability of Model‐Integrated Evidence (MIE) to Demonstrate Bioequivalence ...
Yuqing Gong +17 more
doaj +1 more source
Mechanistic modeling of generic orally inhaled drug products: A workshop summary report
CPT: Pharmacometrics & Systems Pharmacology, 2023 In silico mechanistic modeling approaches have been designed by various stakeholders with the goal of supporting development and approval of generic orally inhaled drug products in the United States.
Ross L. Walenga +12 more
doaj +1 more source
The concept of: Generic drugs and patented drugs Vs brand name drugs and non-proprietary (generic) name drugs. [PDF]
Frontiers in Pharmacology, 2013 Time and again the importance of generic prescribing has been emphasized, primarily to reduce the cost of drugs (Mukherjee, 2013). There are two concepts to be understood here, one is generic vs. patented drugs and the other is a drug's “brand name” vs.
Karan eThakkar, Gauri eBilla
doaj +3 more sources
CPT: Pharmacometrics & Systems Pharmacology, 2022 Physiologically‐based pharmacokinetic models combine knowledge about physiology, drug product properties, such as physicochemical parameters, absorption, distribution, metabolism, excretion characteristics, formulation attributes, and trial design or ...
Nikunjkumar Patel +14 more
doaj +1 more source
Amphotericin B release rate is the link between drug status in the liposomal bilayer and toxicity
Asian Journal of Pharmaceutical Sciences, 2022 Amphotericin B (AmB) is an amphiphilic drug commonly formulated in liposomes and administered intravenously to treat systemic fungal infections. Recent studies on the liposomal drug product have shed light on the AmB aggregation status in the bilayer ...
Yuri Svirkin +13 more
doaj +1 more source